Search Patents
  • Pharmaceutical laser drilling system
    Patent number: 7030338
    Abstract: A laser drilling system forms an opening in the coating of a pharmaceutical dosage form and includes an orienting assembly to correctly orient dosage forms, a debris removal assembly to reduce buildup of and reduce exposure to drilling debris and a quality control assembly to verify that the opening formed conforms to predetermined specifications.
    Type: Grant
    Filed: July 23, 2003
    Date of Patent: April 18, 2006
    Assignee: Pfizer, Inc.
    Inventors: Mark S. Carruthers, Christopher D. Craig, Douglas L. Millard, David D. Newbold, Kenny R. Spence, Avinash G. Thombre
  • Agonist anti-trkC antibodies and methods using same
    Patent number: 7968690
    Abstract: The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy.
    Type: Grant
    Filed: December 23, 2004
    Date of Patent: June 28, 2011
    Assignee: Rinat Neuroscience Corp.
    Inventor: Jaume Pons
  • Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
    Publication number: 20050100509
    Abstract: Methods for detecting acetylcholinesterase in a brain of a patent, comprising administering to the patient a detectable amount of a radiolabeled compound of a class of benzisoxazoles or a pharmaceutically acceptable salt thereof, are disclosed herein. The methods are useful for diagnosing, estimating the severity of, or monitoring the progression of a dementia, such as Alzheimer's disease, in a patient.
    Type: Application
    Filed: March 26, 2004
    Publication date: May 12, 2005
    Applicants: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: J. Frost, Robert Dannals, John Musachio, Ursula Scheffel, Anabella Villalobos, Badreddine Bencherif
  • Cannabinoid receptor ligands and uses thereof
    Patent number: 7268133
    Abstract: Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 11, 2007
    Assignee: Pfizer, Inc. Patent Department
    Inventors: David A. Griffith, Marlys Hammond
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20210198365
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: October 19, 2018
    Publication date: July 1, 2021
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • COMBINATION PRODUCT FOR THE TREATMENT OF CANCER
    Publication number: 20240010731
    Abstract: Methods of administering a therapeutically effective amount of Debio 1143 and a therapeutically effective amount of an anti-PD-L1 antibody or antigen-binding fragment thereof, for the treatment of cancer, are provided.
    Type: Application
    Filed: June 2, 2023
    Publication date: January 11, 2024
    Applicants: Debiopharm International S.A., Merck Patent GmbH, Pfizer Inc.
    Inventors: Grégoire Vuagniaux, Norbert Wiedemann, Claudio Zanna
  • Dosing Regimen of Avelumab for the Treatment of Cancer
    Publication number: 20190330352
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Application
    Filed: October 5, 2017
    Publication date: October 31, 2019
    Applicants: PFIZER INC, MERCK PATENT GmbH
    Inventors: Glen Ian Andrews, Carlo Leonel BELLO, Satjit Singh BRAR, Shaonan WANG, Pascal GIRARD
  • Dosing regimen of avelumab for the treatment of cancer
    Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
    Publication number: 20180369377
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Application
    Filed: December 5, 2016
    Publication date: December 27, 2018
    Applicants: MERCK PATENT GmbH, PFIZER INC.
    Inventors: Gianluca RINALDI, Alessandra DEL RIO, Silvia FRATAR-CANGELI, Senta VOSS, Markus WEIGANDT
  • PD-1/PD-L1 Inhibitors for Cancer Treatment
    Publication number: 20190144545
    Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
    Type: Application
    Filed: May 22, 2017
    Publication date: May 16, 2019
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Dimitry NUYTEN, Alexei MOROZOV, Adrian WOOLFSON, Aron THALL, Kevin CHIN, Satjit BRAR
  • PD-1/PD-L1 inhibitors for the treatment of cancer
    Patent number: 10800846
    Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: October 13, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Jean-Marie Cuillerot, Anja von Heydebreck, Guojun Yuan
  • Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab
    Patent number: 11058769
    Abstract: The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: July 13, 2021
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Gianluca Rinaldi, Alessandra Del Rio, Silvia Fratar-Cangeli, Senta Voss, Markus Weigandt
  • Combination for Treating Cancer
    Publication number: 20210386826
    Abstract: Provided herein are methods and combinations for treating a subject having cancer by administering to the subject a PD-1/PD-L1 axis inhibitor, a CD-122-biased cytokine agonist, and an anti-androgen or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 16, 2021
    Applicants: Pfizer Inc., MERCK PATENT GMBH, NEKTAR THERAPEUTICS, Astellas Pharma Inc.
    Inventors: Christoffel Hendrik Boshoff, Rossano Cesari, Cristian Massacesi, Deborah Charych
  • Combination of a PD-1 Axis Binding Antagonist and an ALK Inhibitor for Treating ALK-Negative Cancer
    Publication number: 20180282415
    Abstract: The present disclosure describes combination therapies useful for the treatment of cancer. In particular, the invention relates to a combination therapy which comprises a PD-1 axis binding antagonist and an ALK inhibitor for treating cancer.
    Type: Application
    Filed: September 27, 2016
    Publication date: October 4, 2018
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Chia-Yang LIN, Wei Wei Wu PRIOR, Yan QU, Changyu WANG
  • Diagnostic Anti-PD-L1 Antibody and Use Thereof
    Publication number: 20190211104
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Application
    Filed: September 20, 2017
    Publication date: July 11, 2019
    Applicants: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia WILM, Klaus SCHNEIDER, Heike DAHMEN
  • PD-L1 Antagonist Combination Treatments
    Publication number: 20180169232
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • PD-L1 antagonist combination treatments
    Patent number: 10869924
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 22, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, Adrian Woolfson
  • Diagnostic anti-PD-L1 antibody and use thereof
    Patent number: 10738120
    Abstract: The present invention provides for an antibody or antigen-binding fragment thereof which binds to an epitope within human PD-L1 with high specificity and reproducibility. The inventive antibody or antigen-binding fragment thereof may be used in assessing PD-L1 expression in tissue samples to aid in patient stratification. The present invention further provides methods of producing the inventive antibody.
    Type: Grant
    Filed: September 20, 2017
    Date of Patent: August 11, 2020
    Assignees: Merck Patent GmbH, Pfizer Inc.
    Inventors: Claudia Wilm, Klaus Schneider, Heike Dahmen
  • CD47 blockade with radiation therapy
    Patent number: 11771764
    Abstract: This patent application relates to the treatment of cancer and other diseases that have a CD47+ phenotype. Treatment involves the use of radiation and a CD47-binding agent, preferably a CD47-binding form of human signal regulatory protein alpha (SIRPa) that inhibits activation of the CD47/SIRPa axis and mediates phagocytosis of CD47+ disease cells. An anti-cancer effect of a CD47 blocking agent is enhanced when combined with radiation therapy. The anti-cancer effect of a CD47 blocking agent such as SIRPaFc is enhanced when combined with radiation therapy.
    Type: Grant
    Filed: November 5, 2018
    Date of Patent: October 3, 2023
    Assignee: Pfizer Inc.
    Inventors: Lei Cui, Lisa Danae Schultz Johnson
  • Method and apparatus for identifying microorganisms
    Patent number: 4288543
    Abstract: The method and apparatus for testing the susceptibility of bacteria to antibiotics described in the U.S. Pat. No. 3,832,532 and related patents are adapted for identifying various strains of bacteria by determining the light scatter indices (LSI) for a special group of antimicrobials, which have particularly significant characteristics with respect to identifying the strains of microorganisms, and analyzing them by a computer method, such as a quadratic discriminant function statistical technique, to identify the microorganisms to which the antimicrobials are applied. It has been found that 14 antimicrobial agents provide an extremely reliable identification and it is believed that the identifying group of agents could be reduced without sacrificing too much reliability. The agents preferably should be those which are not in common therapeutic use to avoid errors resulting from strains which have become immune to various therapeutically-utilized antibiotic agents.
    Type: Grant
    Filed: October 17, 1977
    Date of Patent: September 8, 1981
    Assignee: Pfizer Inc.
    Inventors: Bruce H. Sielaff, Julius Praglin, James E. McKie, Jr., David K. Longhenry, Alan C. Curtiss, Charles B. Bidwell
Narrow Results

Filter by US Classification